NCT04996160 2026-04-17
Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia
Stanford University
Phase 1 Completed
Clinical Trials
6 trialsNCT03526250 2026-04-03
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Completed
NCT03472573 2025-05-15
Palbociclib and Dexamethasone in Treating Participants With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia
Thomas Jefferson University
Phase 1 Completed
NCT03792256 2025-03-21
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
Children's Oncology Group
Phase 1 Completed
NCT00141297 2016-01-05
A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer
Pfizer
Phase 1 Completed
NCT00420056 2015-10-28
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
Pfizer
Phase 1 Completed